+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biopharmaceuticals Market by Product Type, Therapeutic Area, Route Of Administration, Technology, Distribution Channel, End User, Pricing Model - Global Forecast to 2030- Product Image
Biopharmaceuticals Market by Product Type, Therapeutic Area, Route Of Administration, Technology, Distribution Channel, End User, Pricing Model - Global Forecast to 2030- Product Image
Sale

Biopharmaceuticals Market by Product Type, Therapeutic Area, Route Of Administration, Technology, Distribution Channel, End User, Pricing Model - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5665849
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior leaders navigating the biopharmaceuticals market require actionable intelligence to support innovation, investment, and operational resilience. As technological advancement accelerates disruption across therapeutic areas, competitive agility is crucial for sustained growth and value creation.

Market Snapshot: Biopharmaceuticals Market at a Glance

The Biopharmaceuticals Market grew from USD 627.19 billion in 2024 to USD 690.04 billion in 2025. It is expected to continue growing at a CAGR of 9.84%, reaching USD 1.10 trillion by 2030. Accelerating research and development activities, coupled with transformative platforms in cell, gene, and RNA-based therapies, are shaping the competitive environment. Industry leaders face increasing pressure to refine strategies as evolving regulatory policies, digital innovation, and complex supply chains influence every stage from discovery to commercialization.

Scope & Segmentation

  • Product Type: Cell and gene therapies (including CAR T, ex vivo cell therapy, gene editing, viral vectors), monoclonal antibodies (chimeric, fully human, humanized, murine), oligonucleotides (ASO, mRNA therapies, siRNA), peptides (GLP-1 analogs, somatostatin analogs), recombinant proteins (erythropoietin, growth hormones, insulin, interferons), and vaccines (conjugate, live attenuated, mRNA, protein subunit, viral vector formats).
  • Therapeutic Area: Autoimmune disorders, cardiovascular diseases, infectious diseases, neurology, oncology, and rare diseases such as cystic fibrosis and hemophilia.
  • Route of Administration: Inhalation, intravenous, oral (capsules, suspensions, tablets), subcutaneous injections, and topical applications (creams, gels, ointments).
  • Technology: Mammalian and microbial cell culture, hybridoma processes, recombinant DNA, nonviral and viral gene therapy vectors.
  • Distribution Channel: Direct-to-patient, hospital pharmacy, online pharmacy, and retail pharmacy models.
  • End User: Home healthcare (nurse assisted, self-administration), hospitals, specialty clinics.
  • Pricing Model: Biosimilars (insulin analogs, monoclonal antibody biosimilars), generics (peptides, small molecules), innovative products.
  • Regional Coverage: Americas (U.S., Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the U.K., Germany, France, UAE, Saudi Arabia, South Africa), Asia-Pacific (China, India, Japan, Australia, South Korea, and others).
  • Companies Covered: Roche Holding AG, Pfizer Inc., Johnson & Johnson, Merck & Co., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb, Amgen Inc., Gilead Sciences, Inc.

Key Takeaways for Senior Decision-Makers

  • Digital transformation is rapidly advancing R&D efficiency and enhancing clinical trial management, facilitating faster adaptation to emerging therapeutic needs.
  • Collaborative alliances between academia, biotech ventures, and contract organizations are increasing risk-sharing and accelerating the emergence of next-generation modalities across therapeutic areas.
  • Precision medicine and advanced analytics are optimizing patient stratification, supporting tailored interventions and value-based healthcare models.
  • Hybrid supply chain strategies, including onshoring and flexible production technologies, are becoming essential to manage volatility in global sourcing and safeguard continuity.
  • Biosimilars and generics are introducing differentiated pricing frameworks, contributing to expanded market access and adjusted commercialization approaches across geographic regions.

Tariff Impact: Navigating 2025 Regulatory Adjustments

With new US tariffs on active pharmaceutical ingredients and laboratory reagents set for 2025, manufacturers dependent on global supply chains face rising input costs and increased margin pressure. This changing environment is encouraging strategic adjustments, such as supplier diversification, onshoring of production, and greater investment in modular, scalable facilities. Forward-looking enterprises are leveraging automation and advanced analytics to mitigate supply disruptions and offset tariff-driven operational expenses, ultimately fostering a more agile and resilient supply chain ecosystem.

Methodology & Data Sources

This report integrates comprehensive secondary analysis of scientific publications, regulatory filings, and patent data with targeted primary outreach to industry executives, R&D leaders, and regulatory specialists. Quantitative findings have been triangulated from proprietary databases, verified market intelligence sources, and global health registries, ensuring robust segmentation and regional accuracy throughout.

Why This Report Matters

  • Enables senior stakeholders to identify disruptive trends, prioritize investments, and optimize portfolios spanning cell therapies, biologics, and digital innovation.
  • Delivers regional context and granular segmentation, empowering tailored market entry or expansion strategies aligned with shifting policy and payer landscapes.
  • Provides practical recommendations for competitive positioning, operational efficiency, and supply chain resilience amid regulatory, economic, and technology-driven changes.

Conclusion

This report offers a comprehensive roadmap for navigating a complex and evolving biopharmaceutical market. Decision-makers gain clear guidance to drive growth, capitalize on innovation, and address both emerging risks and opportunities across the sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biopharmaceuticals Market, by Product Type
8.1. Introduction
8.2. Cell And Gene Therapies
8.2.1. Car T
8.2.2. Ex Vivo Cell Therapy
8.2.3. Gene Editing
8.2.4. Viral Vectors
8.3. Monoclonal Antibodies
8.3.1. Chimeric
8.3.2. Fully Human
8.3.3. Humanized
8.3.4. Murine
8.4. Oligonucleotides
8.4.1. Aso
8.4.2. Mrna Therapies
8.4.3. Sirna
8.5. Peptides
8.5.1. Glp 1 Analogs
8.5.2. Somatostatin Analogs
8.6. Recombinant Proteins
8.6.1. Erythropoietin
8.6.2. Growth Hormones
8.6.3. Insulin
8.6.4. Interferons
8.7. Vaccines
8.7.1. Conjugate
8.7.2. Live Attenuated
8.7.3. Mrna
8.7.4. Protein Subunit
8.7.5. Viral Vector
9. Biopharmaceuticals Market, by Therapeutic Area
9.1. Introduction
9.2. Autoimmune
9.2.1. Inflammatory Bowel Disease
9.2.2. Psoriasis
9.2.3. Rheumatoid Arthritis
9.3. Cardiovascular
9.3.1. Heart Failure
9.3.2. Hypercholesterolemia
9.3.3. Hypertension
9.4. Infectious Disease
9.4.1. Antibiotics
9.4.2. Antivirals
9.4.3. Vaccines
9.5. Neurology
9.5.1. Alzheimers
9.5.2. Multiple Sclerosis
9.5.3. Parkinsons
9.6. Oncology
9.6.1. Hematological Malignancies
9.6.2. Solid Tumors
9.7. Rare Disease
9.7.1. Cystic Fibrosis
9.7.2. Hemophilia
9.7.3. Lysosomal Storage Disorders
10. Biopharmaceuticals Market, by Route Of Administration
10.1. Introduction
10.2. Inhalation
10.3. Intravenous
10.4. Oral
10.4.1. Capsules
10.4.2. Suspensions
10.4.3. Tablets
10.5. Subcutaneous
10.6. Topical
10.6.1. Creams
10.6.2. Gels
10.6.3. Ointments
11. Biopharmaceuticals Market, by Technology
11.1. Introduction
11.2. Cell Culture
11.2.1. Mammalian
11.2.2. Microbial
11.3. Gene Therapy
11.3.1. Nonviral Vector
11.3.2. Viral Vector
11.4. Hybridoma
11.5. Recombinant Dna
12. Biopharmaceuticals Market, by Distribution Channel
12.1. Introduction
12.2. Direct To Patient
12.3. Hospital Pharmacy
12.4. Online Pharmacy
12.5. Retail Pharmacy
13. Biopharmaceuticals Market, by End User
13.1. Introduction
13.2. Home Healthcare
13.2.1. Nurse Assisted
13.2.2. Self Administration
13.3. Hospitals
13.4. Specialty Clinics
14. Biopharmaceuticals Market, by Pricing Model
14.1. Introduction
14.2. Biosimilars
14.2.1. Insulin Analogs
14.2.2. Mab Biosimilars
14.3. Generics
14.3.1. Peptides
14.3.2. Small Molecules
14.4. Innovative
15. Americas Biopharmaceuticals Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Biopharmaceuticals Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Biopharmaceuticals Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Roche Holding AG
18.3.2. Pfizer Inc.
18.3.3. Johnson & Johnson
18.3.4. Merck & Co., Inc.
18.3.5. AbbVie Inc.
18.3.6. Novartis AG
18.3.7. Sanofi S.A.
18.3.8. Bristol-Myers Squibb Company
18.3.9. Amgen Inc.
18.3.10. Gilead Sciences, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. BIOPHARMACEUTICALS MARKET MULTI-CURRENCY
FIGURE 2. BIOPHARMACEUTICALS MARKET MULTI-LANGUAGE
FIGURE 3. BIOPHARMACEUTICALS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CAR T, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY EX VIVO CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ASO, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MRNA THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GLP 1 ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NONVIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYBRIDOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NURSE ASSISTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 104. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 105. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 106. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 107. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 108. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 109. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 110. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INSULIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 111. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 112. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 113. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 114. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 115. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 116. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 117. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INNOVATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 129. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 130. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 131. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 132. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 134. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 135. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 137. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 138. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 141. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 142. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 143. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 144. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 172. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 174. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 175. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 176. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 177. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 178. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 179. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 180. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 181. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 182. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 183. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 184. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 185. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 186. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 188. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 189. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 190. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 191. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 192. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 195. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 196. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 197. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 198. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 200. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 202. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 203. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 204. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 205. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 206. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 207. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 208. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 209. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 210. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 211. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 212. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 214. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 215. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 217. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 218. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 221. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 222. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 223. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 224. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 226. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 227. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 228. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 229. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 230. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 231. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 232. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 233. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 234. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 235. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 236. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 237. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 238. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 240. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 241. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 242. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 243. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 244. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 247. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 248. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 249. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 250. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 252. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 253. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 254. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 255. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 256. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 257. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 258. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 259. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 260. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 261. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 262. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 263. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 264. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 266. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 267. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 268. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 269. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 270. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 273. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 274. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 275. ARGENTINA BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 306. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 308. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 310. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2030 (USD MILLION)
TABLE 312. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 314. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 316. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 320. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
TABLE 322. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY HOME HEALTHCARE, 2018-2030 (USD MILLION)
TABLE 326. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY PRICING MODEL, 2018-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 328. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, 2018-2030 (USD MILLION)
TABLE 329. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 330. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2030 (USD MILLION)
TABLE 331. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 332. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY OLIGONUCLEOTIDES, 2018-2030 (USD MILLION)
TABLE 333. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY PEPTIDES, 2018-2030 (USD MILLION)
TABLE 334. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 335. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 336. GERMANY BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 337. GERMANY BIOPHARMACEUT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Biopharmaceuticals market report include:
  • Roche Holding AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Novartis AG
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Gilead Sciences, Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 690.04 Billion
Forecasted Market Value ( USD ) by 2030 $ 1100 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biopharmaceutical CMO & CRO Market by Service Type, Product Type, Application, End User - Global Forecast to 2030 - Product Image

Biopharmaceutical CMO & CRO Market by Service Type, Product Type, Application, End User - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Biopharmaceuticals Contract Manufacturing Market by Service Type, Product Type, Technology, Scale, Therapeutic Area - Global Forecast to 2030 - Product Image

Biopharmaceuticals Contract Manufacturing Market by Service Type, Product Type, Technology, Scale, Therapeutic Area - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 225 Pages
  • Global
From
Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030 - Product Image

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Biopharmaceutical Market Outlook to 2029 - Product Image

Biopharmaceutical Market Outlook to 2029

  • Report
  • 97 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.